Neos Therapeutics, Inc. (NASDAQ:NEOS) is reporting third quarter financial results on Monday 9th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, NEOS is expected to report 3Q20 loss of $ 0.05 per share from revenue of $ 15.47 million.
For the full year, analysts anticipate top line of $ 62.72 million, while looking forward to loss of $ 0.31 per share bottom line.
Previous Quarter Performance
Neos Therapeutics, Inc. unwinded loss for the second quarter of $ 0.11 per share, from the revenue of $ 13.13 million. The quarterly revenues declined 16.05 percent compared with the same quarter last year. Street analysts expected Neos Therapeutics, Inc. to report loss of $ 0.13 per share on revenue of $ 12.17 million for the second quarter. The bottom line results beat street analysts by $ 0.02 or 15.38 percent, at the same time, top line results outshined analysts by $ 0.96 million or 7.89 percent.
Stock Performance
On Friday, shares of Neos Therapeutics, Inc. has traded high as $ 0.75 and has cracked $ 0.70 on the downward trend, reaching $ 0.72 with volume of 478.70 thousand shares.
According to the previous trading day, closing price of $ 0.72, representing a 60.00 % increase from the 52 week low of $ 0.45 and a 63.64 % decrease over the 52 week high of $ 1.98.
The company has a market capital of $ 37.34 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Neos Therapeutics, Inc. will be hosting a conference call at 8:30 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.neostx.com
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold.
